Skyrizi

Skyrizi is a biologic that was approved for the treatment of moderate-to-severe plaque psoriasis in 2019. It is also being tested as a treatment for psoriatic arthritis.

What is Skyrizi?

Skyrizi (also known by its generic name risankizumab-rzaa) was approved by the FDA in April 2019 for the treatment of moderate-to-severe plaque psoriasis in adults.

Skyrizi is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterwards.

To learn more, please visit the Skyrizi website.

FDA Approves Skyrizi for Plaque Psoriasis

Learn how Skyrizi could be a treatment option for you and your psoriasis.

Find out more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Get the latest news on new treatment options from NPF.

Stay up to date

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorMy Psoriasis Team logo

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.